Näytä suppeat kuvailutiedot

dc.contributor.authorPalmu, Joonatan
dc.contributor.authorBörschel, Christin S.
dc.contributor.authorOrtega-Alonso, Alfredo
dc.contributor.authorMarkó, Lajos
dc.contributor.authorInouye, Michael
dc.contributor.authorJousilahti, Pekka
dc.contributor.authorSalido, Rodolfo A.
dc.contributor.authorSanders, Karenina
dc.contributor.authorBrennan, Caitriona
dc.contributor.authorHumphrey, Gregory C.
dc.contributor.authorSanders, Jon G.
dc.contributor.authorGutmann, Friederike
dc.contributor.authorLinz, Dominik
dc.contributor.authorSalomaa, Veikko
dc.contributor.authorHavulinna, Aki S.
dc.contributor.authorForslund, Sofia K.
dc.contributor.authorKnight, Rob
dc.contributor.authorLahti, Leo
dc.contributor.authorNiiranen, Teemu
dc.contributor.authorSchnabel, Renate B.
dc.date.accessioned2023-05-04T06:37:11Z
dc.date.available2023-05-04T06:37:11Z
dc.date.issued2023
dc.identifier.citationPalmu, J., Börschel, C. S., Ortega-Alonso, A., Markó, L., Inouye, M., Jousilahti, P., Salido, R. A., Sanders, K., Brennan, C., Humphrey, G. C., Sanders, J. G., Gutmann, F., Linz, D., Salomaa, V., Havulinna, A. S., Forslund, S. K., Knight, R., Lahti, L., Niiranen, T., & Schnabel, R. B. (2023). Gut microbiome and atrial fibrillation : results from a large population-based study. <i>EBioMedicine</i>, <i>91</i>, Article 104583. <a href="https://doi.org/10.1016/j.ebiom.2023.104583" target="_blank">https://doi.org/10.1016/j.ebiom.2023.104583</a>
dc.identifier.otherCONVID_182960828
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/86756
dc.description.abstractBackground Atrial fibrillation (AF) is an important heart rhythm disorder in aging populations. The gut microbiome composition has been previously related to cardiovascular disease risk factors. Whether the gut microbial profile is also associated with the risk of AF remains unknown. Methods We examined the associations of prevalent and incident AF with gut microbiota in the FINRISK 2002 study, a random population sample of 6763 individuals. We replicated our findings in an independent case–control cohort of 138 individuals in Hamburg, Germany. Findings Multivariable-adjusted regression models revealed that prevalent AF (N = 116) was associated with nine microbial genera. Incident AF (N = 539) over a median follow-up of 15 years was associated with eight microbial genera with false discovery rate (FDR)-corrected P < 0.05. Both prevalent and incident AF were associated with the genera Enorma and Bifidobacterium (FDR-corrected P < 0.001). AF was not significantly associated with bacterial diversity measures. Seventy-five percent of top genera (Enorma, Paraprevotella, Odoribacter, Collinsella, Barnesiella, Alistipes) in Cox regression analyses showed a consistent direction of shifted abundance in an independent AF case–control cohort that was used for replication. Interpretation Our findings establish the basis for the use of microbiome profiles in AF risk prediction. However, extensive research is still warranted before microbiome sequencing can be used for prevention and targeted treatment of AF. Funding This study was funded by European Research Council, German Ministry of Research and Education, Academy of Finland, Finnish Medical Foundation, and the Finnish Foundation for Cardiovascular Research, the Emil Aaltonen Foundation, and the Paavo Nurmi Foundation.en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherElsevier BV
dc.relation.ispartofseriesEBioMedicine
dc.rightsCC BY-NC-ND 4.0
dc.subject.otheratrial fibrillation
dc.subject.othergut microbiome
dc.subject.othermetagenomics
dc.subject.otherepidemiology
dc.titleGut microbiome and atrial fibrillation : results from a large population-based study
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202305042850
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.relation.issn2352-3964
dc.relation.volume91
dc.type.versionpublishedVersion
dc.rights.copyright© 2023 The Author(s). Published by Elsevier B.V.
dc.rights.accesslevelopenAccessfi
dc.subject.ysorytmihäiriöt
dc.subject.ysoriskitekijät
dc.subject.ysosuolistomikrobisto
dc.subject.ysoeteisvärinä
dc.subject.ysoepidemiologia
dc.subject.ysosydän- ja verisuonitaudit
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p9887
jyx.subject.urihttp://www.yso.fi/onto/yso/p13277
jyx.subject.urihttp://www.yso.fi/onto/yso/p37925
jyx.subject.urihttp://www.yso.fi/onto/yso/p21917
jyx.subject.urihttp://www.yso.fi/onto/yso/p11307
jyx.subject.urihttp://www.yso.fi/onto/yso/p9886
dc.rights.urlhttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.relation.doi10.1016/j.ebiom.2023.104583
jyx.fundinginformationRBS has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 648131, from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 847770 (AFFECT-EU) and German Center for Cardiovascular Research (DZHK e.V.) (81Z1710103); German Ministry of Research and Education (BMBF 01ZX1408A) and ERACoSysMed3 (031L0239). ASH has received funding from the Academy of Finland (321356). TN has received funding from the Academy of Finland (321351), the Emil Aaltonen Foundation, and Finnish Medical Foundation, and the Finnish Foundation for Cardiovascular Research. LL has received funding from the Academy of Finland (295741). VS was supported by the Finnish Foundation for Cardiovascular research. JP was supported by the Paavo Nurmi Foundation. SKF has received funding from the German Center for Cardiovascular Research (DZHK e.V., Standort Berlin MDC) (81Z0100113) and the German Research Foundation (DFG, SFB1470).
dc.type.okmA1


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot

CC BY-NC-ND 4.0
Ellei muuten mainita, aineiston lisenssi on CC BY-NC-ND 4.0